# Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Non Erosive Reflux Disease

> **NCT02556021** · PHASE3 · COMPLETED · sponsor: **HK inno.N Corporation** · enrollment: 324 (actual)

## Conditions studied

- Non-erosive Reflux Disease

## Interventions

- **DRUG:** CJ-12420 50mg
- **DRUG:** CJ-12420 100mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02556021
- **Lead sponsor:** HK inno.N Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-22
- **Primary completion:** 2016-11-01
- **Final completion:** 2016-11-01
- **Target enrollment:** 324 (ACTUAL)
- **Last updated:** 2018-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02556021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02556021, "Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Non Erosive Reflux Disease". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT02556021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*